title: Mass concentration of plasma phospholipid transfer protein in normolipidemic, type IIa hyperlipidemic, type IIb hyperlipidemic, and non-insulin-dependent diabetic subjects as measured by a specific ELISA.
abstract: Mean plasma phospholipid transfer protein (PLTP) concentrations were measured for the first time by using a competitive enzyme-linked immunosorbent assay. PLTP mass levels and phospholipid transfer activity values, which were significantly correlated among normolipidemic plasma samples (r=0.787, P<0.0001), did not differ between normolipidemic subjects (3.95+/-1.04 mg/L and 575+/-81 nmol. mL-1. h-1, respectively; n=30), type IIa hyperlipidemic patients (4. 06+/-0.84 mg/L and 571+/-43 nmol. mL-1. h-1, respectively; n=36), and type IIb hyperlipidemic patients (3.90+/-0.79 mg/L and 575+/-48 nmol. mL-1. h-1, respectively; n=33). No significant correlations with plasma lipid parameters were observed among the various study groups. In contrast, plasma concentrations of the related cholesteryl ester transfer protein (CETP) were higher in type IIa and type IIb patients than in normolipidemic controls, and significant, positive correlations with total and low density lipoprotein cholesterol levels were noted. Interestingly, plasma PLTP mass concentration and plasma phospholipid transfer activity were significantly higher in patients with non-insulin-dependent diabetes mellitus (n=50) than in normolipidemic controls (6.76+/-1. 93 versus 3.95+/-1.04 mg/L, P<0.0001; and 685+/-75 versus 575+/-81 nmol. mL-1. h-1, P<0.0001, respectively). In contrast, CETP levels did not differ significantly between the 2 groups. Among non-insulin-dependent diabetes mellitus patients, PLTP levels were positively correlated with fasting glycemia and glycohemoglobin levels (r=0.341, P=0.0220; and r=0.382, P=0.0097, respectively) but not with plasma lipid parameters. It is proposed that plasma PLTP mass levels are related to glucose metabolism rather than to lipid metabolism.
authors.affiliation: Laboratoire de Biochimie des Lipoprotéines, INSERM U498, Université de Bourgogne Point, Dijon, France.
authors.forename: C
authors.initials: C
authors.lastname: Desrumaux
authors.forename: A
authors.initials: A
authors.lastname: Athias
authors.forename: G
authors.initials: G
authors.lastname: Bessède
authors.forename: B
authors.initials: B
authors.lastname: Vergès
authors.forename: M
authors.initials: M
authors.lastname: Farnier
authors.forename: L
authors.initials: L
authors.lastname: Perségol
authors.forename: P
authors.initials: P
authors.lastname: Gambert
authors.forename: L
authors.initials: L
authors.lastname: Lagrost
mesh_terms: D002352:Carrier Proteins / Q000097:blood* / Q000276:immunology / Q000302:isolation & purification; D053480:Cholesterol Ester Transfer Proteins; D003924:Diabetes Mellitus, Type 2 / Q000097:blood*; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods*; D005260:Female; D006023:Glycoproteins; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood*; D007106:Immune Sera / Q000276:immunology; D008055:Lipids / Q000097:blood*; D008297:Male; D008565:Membrane Proteins / Q000097:blood* / Q000276:immunology / Q000302:isolation & purification; D009994:Osmolar Concentration; D049294:Phospholipid Transfer Proteins; D012016:Reference Values